Evidence map›Paper›PMID 25445946›Full record

ReviewEuropean respiratory review : an official journal of the European Respiratory Society2014

The right ventricle in pulmonary arterial hypertension.

Robert Naeije, Alessandra Manes

2 registry-linked trialsOpen access · diamondAbstract readCase ReportsReview
In one paragraph

Review in European respiratory review : an official journal of the European Respiratory Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04092855 unknown statusnot on this mapstarted 2018, after this paper: background citation

Early Identification and Prediction of Right Ventricular Dysfunction and Failure in Critically Ill Patients: An Observational Non-Interventional Cohort Study

TypeobservationalSponsorMontreal Heart InstituteRan2018 to 2024Enrolled112ConditionsRight Ventricular Dysfunction, Right Heart Failure, Congestive Heart Failure
NCT04782154 completednot on this mapstarted 2021, after this paper: background citation

Paceport Swan-Ganz Data Collection Study

TypeobservationalSponsorMontreal Heart InstituteRan2021 to 2022Enrolled136ConditionsRight Ventricular Dysfunction, Right Heart Failure, Congestive Heart Failure
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 260 citations in OpenAlex.

  1. Trial
  2. Trial
  3. The pathophysiology of wild-type transthyretin amyloidosis: implications for exercise intolerance.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Prognostic Value of the RVFWLS/PASP Ratio in Pulmonary Arterial Hypertension.Journal of cardiovascular development and disease · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Robert NaeijeDept of Cardiology, Erasme University Hospital, Brussels, Belgium. Dept of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy. rnaeije@ulb.ac.be.
Alessandra ManesDept of Cardiology, Erasme University Hospital, Brussels, Belgium. Dept of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.
Mie University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a right heart failure syndrome. In early-stage PAH, the right ventricle tends to remain adapted to afterload with increased contractility and little or no increase in right heart chamber dimensions. However, less than optimal right ventricular (RV)-arterial coupling may already cause a decreased aerobic exercise capacity by limiting maximum cardiac output. In more advanced stages, RV systolic function cannot remain matched to afterload and dilatation of the right heart chamber progressively develops. In addition, diastolic dysfunction occurs due to myocardial fibrosis and sarcomeric stiffening. All these changes lead to limitation of RV flow output, increased right-sided filling pressures and under-filling of the left ventricle, with eventual decrease in systemic blood pressure and altered systolic ventricular interaction. These pathophysiological changes account for exertional dyspnoea and systemic venous congestion typical of PAH. Complete evaluation of RV failure requires echocardiographic or magnetic resonance imaging, and right heart catheterisation measurements. Treatment of RV failure in PAH relies on: decreasing afterload with drugs targeting pulmonary circulation; fluid management to optimise ventricular diastolic interactions; and inotropic interventions to reverse cardiogenic shock. To date, there has been no report of the efficacy of drug treatments that specifically target the right ventricle.

Indexed as

Adaptation, PhysiologicalBlood PressureCardiac OutputChildExercise ToleranceFemaleHeart VentriclesHumansHypertension, PulmonaryMalePrognosisVentricular Dysfunction, RightYoung Adult

Identifiers

PMID25445946
PMCPMC9487395
OpenAlexW2134780421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.